SCHEMBL5694355

SCHEMBL5694355

CC(=O)OCCOc1ccccc1C

nearest known ligand 0.57

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 5/20 0.56
L3MBTL1 Q9Y468 2/20 0.55
MAPT P10636 2/20 0.53
LMNA P02545 2/20 0.53
SMN1; SMN2 Q16637 2/20 0.53
NPC1 O15118 1/20 0.53
RAB9A P51151 1/20 0.53
THRB P10828 1/20 0.50
KDM4E B2RXH2 5/20 0.49
ALDH1A1 P00352 5/20 0.49
MCL1 Q07820 1/20 0.48
NR2F2 P24468 1/20 0.48
HTT P42858 1/20 0.48
RXRA P19793 1/20 0.47
RXRB P28702 1/20 0.47
RXRG P48443 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10030191 0.89 TDP1 (0.55) TDP1L3MBTL1MAPTLMNASMN1; SMN2
SCHEMBL1108095 0.87 TDP1 (0.48) TDP1L3MBTL1MAPTLMNASMN1; SMN2
SCHEMBL649097 0.83 TDP1 (0.51) TDP1L3MBTL1MAPTLMNASMN1; SMN2
SCHEMBL31426927 0.83 TDP1 (0.51) TDP1L3MBTL1MAPTLMNASMN1; SMN2
SCHEMBL9780126 0.83 TDP1 (0.68) TDP1L3MBTL1MAPTLMNASMN1; SMN2
SCHEMBL1592876 0.82 TDP1 (0.60) TDP1L3MBTL1MAPTLMNASMN1; SMN2
SCHEMBL17034019 0.81 SMN1; SMN2 (0.41) TDP1L3MBTL1MAPTLMNASMN1; SMN2
SCHEMBL17459123 0.81 L3MBTL1 (0.64) TDP1L3MBTL1MAPTLMNASMN1; SMN2
SCHEMBL9469278 0.81 TDP1 (0.49) TDP1L3MBTL1MAPTLMNASMN1; SMN2
SCHEMBL5706209 0.81 CYP1A2 (0.56) TDP1L3MBTL1MAPTLMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8765764-B2 2-acylaminothiazole derivative or salt thereof ASTELLAS PHARMA, INC. (JP) 2014-07-01 US disclosed
US-20130079351-A1 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF ASTELLAS PHARMA, INC. (JP) 2013-03-28 US disclosed
EP-1153085-B1 DISAZO DYES AND INKS CONTAINING THEM FUJIFILM IMAGING COLORANTS LTD (GB) 2006-05-17 EP disclosed
US-6712893-B1 BLACK INKS WITH GOOD STORAGE STABILITY; IMAGES WITH GOOD OPTICAL DENSITY AND COLORFASTNESS AVECIA LIMITED (GB) 2004-03-30 US disclosed
EP-1153085-A2 DISAZO DYES AND INKS CONTAINING THEM Avecia Limited (GB) 2001-11-14 EP disclosed
WO-2000043453-A2 DISAZO DYES AND INKS CONTAINING THEM AVECIA LIMITED (GB) 2000-07-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130079351-A1 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF MPL, JAK2, ABL1 TDP1 4760/4885L3MBTL1 1136/4885MAPT 4550/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.